Chemotherapy remains of limited use for the treatment of prostate cancer with only one drug, docetaxel, demonstrating a modest survival advantage for treatment of hue-stage disease. Data from the NCI 60 cell line screen indicated, that the castration-resistant prostate cancer cell lines PC3 and DU 145 were more sensitive than average to the novel polymeric fluoropyrimidine (FP), F10, despite displaying less than average sensitivity to the widely-used FP, SFU. In an embodiment of the present invention, F10 treatment of PC3 xenografts results in a significant survival advantage (treatment to control ratio (T/C) days = 18 p < 0.001 n = 16) relative to control mice treated with saline. F10 (40 mg/kg/dose) was administered via jugular vein catheterization 3-times per week for five weeks. This aggressive dosing regimen was completed with no drug-induced weight loss and. with no evidence of toxicity. F10 was also shown to sensitize PC3 cells to radiation and F10 was also shown to be a potent radiosensitixer of PC3 xenografts in vivo with F10 in combination with radiation resulting in significantly greater regression of PC3 xenografts than radiation alone. The results indicate that F10 in this pre-clinical setting is an effective chemotherapeutie agent and possesses significant radiosensitizing properties.La chimiothérapie reste dune utilisation limitée dans le traitement du cancer de la prostate avec un seul médicament, le docétaxel, démontrant un faible avantage de survie pour le traitement dune maladie à un stade nuancé. Des données issues du criblage de lignée cellulaire NCI 60 ont indiqué que les lignées cellulaires PC3 et DU 145 du cancer de la prostate résistant à la castration étaient plus sensibles que la moyenne au nouveau fluoropyrimidine polymère (FP), F10, en dépit dune sensibilité inférieure à la moyenne au FP largement utilisé, le SFU. Dans un mode de réalisation de la présente invention, le traitement par F10 de xénogreffes PC3 permet dobtenir un avantage de
